Mark Your Calendar: SpaceX Could Be a Very Different Stock After June 12

SpaceX is reportedly targeting an IPO on June 12 with a $135 share price, implying a $1.77 trillion valuation and up to $75 billion in new capital raised. The article cautions that Morningstar sees the company as significantly overvalued, estimating fair value closer to $780 billion and advising investors to wait for post-IPO volatility to subside. The piece is primarily a valuation warning rather than a fundamental business update.

Analysis

The market is likely misreading this as a simple IPO valuation debate; the more important setup is a post-listing supply/demand imbalance. A high-profile, oversubscribed debut often creates an initial scarcity premium, but that premium can unwind quickly once lockup math, early employee monetization, and index-inclusion mechanics start to matter over the next 1-3 quarters. In other words, the cleaner trade is often not the IPO print itself but the volatility compression that follows once ownership broadens.

For NVDA and INTC, the second-order effect is not direct revenue exposure but narrative contamination: if the market starts discounting the AI monetization assumptions embedded in a marquee new issue, it can briefly cool speculative appetite across the AI complex. That is usually a short-duration factor, but it can matter because crowded long-only positioning in semis tends to make valuations more sensitive to sentiment than to near-term fundamentals. If the IPO trades poorly, expect a sympathy derating in other AI-adjacent names before fundamentals reassert themselves.

MORN is the cleaner relative-value beneficiary. When a highly promoted deal is questioned, investors tend to reach for independent verification, diligence, and valuation discipline, which supports demand for research franchises and may modestly improve pricing power for trusted data/analytics providers. The flip side is that the broader negative tone around valuation skepticism can also cap upside in the near term if the market interprets this as a warning shot on stretched growth narratives.

The contrarian read is that consensus may be overestimating the persistence of any post-IPO weakness. If the deal prices inside range and the first few sessions hold above issue, sidelined capital may chase the name aggressively, forcing an upward repricing rather than a post-debut fade. The real catalyst to watch is whether the stock can maintain relative strength after the first wave of flipping ends; if it does, the bearish valuation call loses force quickly.

Key Decisions for Investors

• Do not chase the IPO on day 1; wait 2-6 weeks for price discovery and lockup-related supply to surface. Risk/reward is better if the stock trades 15-25% below issue after the initial hype cycle.
• If listed, structure a tactical short-dated put spread on the new issue or a bearish call spread into the first 1-3 weeks to monetize implied volatility compression. Best risk/reward is if IV stays elevated above realized volatility.
• Relative-value trade: long MORN / short a basket of crowded AI-beta proxies for 1-2 months if the market starts demanding more independent valuation scrutiny. This is a sentiment trade, not a fundamentals beta trade.
• Use NVDA and INTC as sentiment gauges, not direct shorts; if the IPO weakens and semis sell off 3-5% on sympathy, fade the move with tight stops because any spillover should be short-lived unless broader AI spending data rolls over.
• Set a trigger to buy the post-IPO dip only if the stock stabilizes after the first unlock/flip window and holds above the IPO midpoint for 5-10 sessions; that would signal real institutional demand rather than retail momentum.